Presentation is loading. Please wait.

Presentation is loading. Please wait.

(A) Graph showing the changes in liver function tests over time for case 1, with a summary of systemic treatments given over time. (A) Graph showing the.

Published byLilian Flowers Modified over 6 years ago

Similar presentations

Presentation on theme: "(A) Graph showing the changes in liver function tests over time for case 1, with a summary of systemic treatments given over time. (A) Graph showing the."— Presentation transcript:

1 (A) Graph showing the changes in liver function tests over time for case 1, with a summary of systemic treatments given over time. (A) Graph showing the changes in liver function tests over time for case 1, with a summary of systemic treatments given over time. The right y-axis refers to bilirubin levels, the left y-axis refers to ALP and ALT levels. (B) Photomicrograph of a representative H&E section from a liver biopsy in case 1. This section shows severe hepatic steatosis, and includes portal tracts without discernible bile ducts. (C) Photomicrograph showing cytokeratin 7 immunohistochemistry of a representative section from a liver biopsy in case 1. This confirms the absence of bile ducts, and demonstrates slight and focal intermediate hepatobiliary phenotype. ALP, alkaline phosphatase; ALT, alanine aminotransferase; CS, corticosteroids; M, mycophenolate mofetil; U, ursodeoxycholic acid; ULN, upper limit of normal. Gary Joseph Doherty et al. ESMO Open 2017;2:e000268 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "(A) Graph showing the changes in liver function tests over time for case 1, with a summary of systemic treatments given over time. (A) Graph showing the."

Similar presentations

The “mickey mouse” sign is made up of the three portal structures

The “mickey mouse” sign is made up of the three portal structures
Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved.
The typical course of acute and chronic hepatitis C

The typical course of acute and chronic hepatitis C
Proposal of a simplified treatment algorithm in patients with cancer and liver cirrhosis. 1 Both tumour- and liver-related prognosis should be taken into.

Proposal of a simplified treatment algorithm in patients with cancer and liver cirrhosis. 1 Both tumour- and liver-related prognosis should be taken into.
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,

A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,
The management of childhood liver diseases in adulthood

The management of childhood liver diseases in adulthood
Primary biliary cirrhosis, AMA negative

Primary biliary cirrhosis, AMA negative
Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
(A) Graph showing the changes in liver function tests over time for case 2, with a summary of systemic treatments given over time. The right y-axis refers.

(A) Graph showing the changes in liver function tests over time for case 2, with a summary of systemic treatments given over time. The right y-axis refers.
Chronic Cholestasis with Dilation of Intrahepatic Bile Duct Related to Administration of Ceritinib  Taizou Hirano, MD, PhD, Mitsuhiro Yamada, MD, PhD,

Chronic Cholestasis with Dilation of Intrahepatic Bile Duct Related to Administration of Ceritinib  Taizou Hirano, MD, PhD, Mitsuhiro Yamada, MD, PhD,
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Herbs and Liver Injury: A Clinical Perspective

Herbs and Liver Injury: A Clinical Perspective
(A) Graph showing the changes in liver function tests over time for case 3, with a summary of systemic treatments given over time. The right y-axis refers.

(A) Graph showing the changes in liver function tests over time for case 3, with a summary of systemic treatments given over time. The right y-axis refers.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Similar presentations

Ads by Google